Related Experiment Video
Updated: Aug 9, 2026
07:52
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
Philip Went1, Claudio Agostinelli, Andrea Gallamini
1Institute of Hematology and Clinical Oncology L. and A. Seràgnoli, Hematology and Hematopathology Units, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Summary
Peripheral T-cell lymphoma (PTCL) subtypes show varied protein expression. A new prognostic score, incorporating patient and tumor factors like Ki-67, improves outcome prediction over existing methods for PTCL.
Area of Science:
- Hematology
- Oncology
- Immunopathology
Background:
- Peripheral T-cell lymphoma, unspecified (PTCL/U) is common in Western countries.
- Limited studies have assessed the impact of phenotype on survival using a wide marker panel in PTCL.
- Angioimmunoblastic T-cell lymphoma (AILD) is another significant PTCL subtype.
Purpose of the Study:
- To evaluate the expression of 19 markers in a large series of PTCL/U and AILD.
- To assess the impact of tumor phenotype on patient survival in PTCL.
- To develop a new prognostic index for PTCL based on phenotype and clinical factors.
Main Methods:
- Immunohistochemistry and in situ hybridization on tissue microarrays.
- Analysis of 148 PTCL/U and 45 AILD cases.
- Retrospective review of clinical data for 93 PTCL/U patients, including those in a prior prognostic index study.
Main Results:
- Aberrant CD5 and/or CD7 expression was typical for PTCLs (PTCL/U and AILD).
- Epstein-Barr virus-associated small RNAs and CD15 expression were adverse prognostic factors.
- A new prognostic score including age, LDH, performance status, and Ki-67 > or = 80% showed improved prediction (P < .0001) compared to the prognostic index (PIT) (P = .0043).
Conclusions:
- PTCLs exhibit a wide range of protein expression.
- A novel prognostic index combining patient and tumor factors was developed.
- This new score may serve as a basis for future prospective therapeutic trials in PTCL.